Half a Loaf is Not Good Enough

President George W. Bush announced on Aug. 9 in a nationally televised address to the nation that he had decided to restrict public funding for embryonic stem cell research to only those cell lines already in existence as of that day. He said at the time that there were 60 cell lines in existence around the world and that these should prove adequate to allow embryonic stem cell research to proceed (See also, "Stem Cells: Steady Momentum for Funding"). He also made it very clear that he would opp

Written byArthur Caplan
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Bush's position was presented as a compromise. And many in the media, in the religious community, and in high political office accepted it as such. So have many in bioethics.

The Bush compromise is no compromise. It is an absolute ban on embryonic stem cell research. The cells lines that exist are not readily available for research. And if the president is to be taken at his word, he will oppose any derivation of new cell lines. Does anyone in the scientific community really believe that it will be possible to see what human embryonic stem cells can do in the battle against disease and disability using the cell lines that currently exist? And if not, why aren't those in leadership positions saying so loudly and clearly?

Existing cell lines will never be adequate to see what the potential is of human embryonic stem cells. Many of the cell lines ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies